- Home
- BNR vs NXN Comparison
BNR vs NXN Comparison
Compare BNR & NXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- NXN
- Stock Information
- Founded
- BNR 2014
- NXN 1992
- Country
- BNR China
- NXN United States
- Employees
- BNR N/A
- NXN N/A
- Industry
- BNR Medical Specialities
- NXN Trusts Except Educational Religious and Charitable
- Sector
- BNR Health Care
- NXN Finance
- Exchange
- BNR Nasdaq
- NXN Nasdaq
- Market Cap
- BNR 38.3M
- NXN 45.4M
- IPO Year
- BNR 2020
- NXN N/A
- Fundamental
- Price
- BNR $4.68
- NXN $11.42
- Analyst Decision
- BNR
- NXN
- Analyst Count
- BNR 0
- NXN 0
- Target Price
- BNR N/A
- NXN N/A
- AVG Volume (30 Days)
- BNR 17.3K
- NXN 9.7K
- Earning Date
- BNR 08-21-2025
- NXN 01-01-0001
- Dividend Yield
- BNR N/A
- NXN 4.23%
- EPS Growth
- BNR N/A
- NXN N/A
- EPS
- BNR N/A
- NXN 0.24
- Revenue
- BNR $72,112,038.00
- NXN N/A
- Revenue This Year
- BNR $136.32
- NXN N/A
- Revenue Next Year
- BNR N/A
- NXN N/A
- P/E Ratio
- BNR N/A
- NXN $48.42
- Revenue Growth
- BNR 0.53
- NXN N/A
- 52 Week Low
- BNR $2.18
- NXN $10.64
- 52 Week High
- BNR $7.90
- NXN $12.45
- Technical
- Relative Strength Index (RSI)
- BNR 69.57
- NXN 37.30
- Support Level
- BNR $4.47
- NXN $11.49
- Resistance Level
- BNR $4.96
- NXN $11.60
- Average True Range (ATR)
- BNR 0.25
- NXN 0.11
- MACD
- BNR 0.11
- NXN -0.02
- Stochastic Oscillator
- BNR 84.31
- NXN 3.39
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.